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Abstract
Newly identified beta-coronavirus i.e. the 2019 novel coronavirus is associated 
with a contagious transmittable respiratory disease called COVID-19. This disease 
has been declared as a “pandemic” by the World Health Organization (WHO). The 
entry of coronavirus in the human respiratory epithelial cells depends upon the 
interaction between host cell receptor ACE2 and viral S-glycoprotein. However, 
this type of molecular recognition in between cell surface receptors and envelope 
glycoproteins are mediated by specific glycan epitopes and attribute to viral entry 
through membrane fusion. Glycans are essential biomolecules made by all living 
organisms, have roles in serving structure, energy storage, and system regulatory 
purposes. The glycan shield plays a crucial role in concealing the surface S protein 
from molecular recognition. The immunomodulatory properties of Glycan-binding 
proteins (GBPs) like Lectins, build them as an attractive candidates for vaccine 
adjuvant. Investigations involving the complement system activation by the lectin 
pathway in COVID-19 and diseases are in need of the hour. The innate immune 
response involving complement system could have varied biological effects against 
an array of microbial infections. The advances in glycoprotein style methods 
especially immunomodulatory action of some lectins are necessary to boost the 
effectiveness of treatment of COVID-19 and other pandemics.
Keywords: Glycan, S-glycoprotein, ACE2 receptor, Glycan binding protein (GBP), 
COVID-19
1. Introduction
A new virus called the 2019 novel coronavirus (an enveloped beta-coronavirus) 
is identified in December 2019 and associated with a de novo contagious respiratory 
disease. The coronavirus disease 2019 (COVID-19) has been declared as a “pan-
demic” by the World Health Organization (WHO). Previous reports have recog-
nized various human coronaviruses, like in 2003 SARS-CoV, in 2004 HCoVNL63, 
in 2005 HKU1, in 2012 MERS-CoV, and now in 2019 pathogenic SARS-CoV-2. In 
humans, the effects of these viruses are correlated with severe respiratory tract 
infections. COVID-19 disease has signs that are similar to a common cold. However, 
this infection can lead to serious respiratory failure, as well as compromised and 
harmful immune responses. Increased monocyte-neutrophil ratios and exacerbated 
release of inflammatory mediators particularly IL-6, characterize this condition, 
which can contribute to organ dysfunction. Given the fact that other coronavirus 
outbreaks have occurred, there is no known treatment or vaccination for COVID-19.
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Another major problem is the urgent need for easy and fast instruments to 
detect viruses in clinical and environmental samples. Early identification of SARS-
CoV-2 in asymptomatic and/or presymptomatic individuals is crucial for stopping 
the transmission chain [1]. Plasmapheresis is also essential for extracorporeal 
removal of SARS-CoV-2 from blood in order to present alternative therapies. These 
dynamic pictures have imposed a fight against time through numerous fields of 
knowledge such as biomedical research, biotechnology, drug production, and 
molecular analysis in order to find as many resolutions as possible to these and other 
complications presented by the pandemic.
Viral members of the CoVs family restrain a positive-sense, single-strand RNA 
genome, which are 26 to 32- kilo bases in length [1]. The infectivity and immeasur-
able distribution capacity of CoVs have been established them as an important 
pathogen. In addition to numerous avian hosts, various members of CoVs have 
been recognized in a range of mammals, like masked palm civets, bats, dogs, mice, 
camels, and cats are responsible for disease related to gastrointestinal systems, 
hepatic, respiratory, and nervous system in humans. The outer surface membrane 
(M), envelope (E), and spike (S) structural proteins are coupled within the enve-
lope of coronavirus which consists of a lipid bilayer. It is believed that glycosylated 
SARS-CoV-2 spike (S) protein, mediates host cell entry by binding to the angioten-
sin- converting enzyme 2 (ACE2) and establish the host tropism. Similar to many 
other viral fusion proteins, the SARS-CoV-2 spikes also utilize a highly dense coat-
ing of non-immunogenic or weakly immunogenic complex carbohydrates - glycan 
shield to thwart the host immune response [2]. Glycans are carbohydrate-based 
polymers made by all living organisms. The heavily glycosylated SARS-CoV spike 
protein suppresses almost 23 putative N-glycosylation sites, amidst 12 of them are 
effectively glycosylated [3]. In viral fusion proteins presence of N-glycan coating is 
correlated with protein glycosylation and plays a decisive role in viral pathogenesis. 
The N-glycans expressed on the surface of viral envelope glycoproteins have very 
diverse biological roles and are all inextricably linked to their nature. However, 
molecular recognition in between cell surface receptors and envelope glycoproteins 
are mediated by specific N-glycan epitopes and attribute to viral entry through 
membrane fusion. Moreover, an extremely dense coating of non-immunogenic or 
feeble immunogenic complicated carbohydrates on otherwise perilously exposed 
viral proteins constitutes an ideal camouflage (or shield) to evade the system [4].
The glycan shield plays a crucial role in concealing the surface S protein from 
molecular recognition. However, to effectively perform, the spike has to acknowl-
edge and bind to ACE2 receptors as the primary infection route. For this reason, the 
RBM should become absolutely exposed and accessible. During this situation, the 
glycan shield works as one with an outsized conformational modification that per-
mits the RBD to emerge higher than the N-glycan coverage. Each the S-glycoprotein 
and ACE2 receptor are proverbial to be extensively glycosylated, i.e. they contain 
covalently linked complex oligosaccharides referred to as glycans. Recently pub-
lished studies have shown that the spike glycoprotein contains sixty-six glycosyl-
ation sites with forty-four of them being enclosed within the model. Another recent 
study analyzed site-specific N-linked glycosylation of MERS and respiratory illness 
SARS S glycoproteins, indicating that every of those glycosylation sites is occupied 
by up to 10 totally different glycans (called glycoforms), which greatly extends 
epitope diversity [4, 5].
The synthesis, folding, and glycosylation (as alternative PTMs) of infectious 
agent proteins depend upon host organelles (ribosome, endoplasmic reticulum, 
and Golgi apparatus) and enzymes (glycosyltransferases and glycosidases). 
The present experimental knowledge relating to the glycosylation of viral 
proteins depends on the carbohydrate processing enzymes present within the 
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biological systems accustomed to propagate the viral strain. During this sense, 
our data regarding the natural pattern of viral protein glycosylation is incredibly 
restricted. It’s conjointly vital to think that viral proteins could follow totally 
different pathways than those discovered from host glycoproteins [5, 6]. Attribute 
to their chemical complexity and restricted sensitivity of existing analytical 
instruments, glycans are left neglected. This can be unfortunate as they verify 
a major part of the structure and performance of the many glycoproteins. This 
can be very true within the field of host/pathogen interactions, wherever glycan 
diversity is employed by each host to evade recognition by pathogens and there-
fore the pathogens to flee the system response. Moreover, glycans, and specifically 
their outmost components, have vital conformational flexibility. This contributes 
to the overall conformational dynamics of the molecule that may each generate 
novel potential drug binding sites or shield binding sites predicted mainly from 
polypeptide-only models [7].
Beyond a function in shielding the underlying proteins from recognition by 
antibodies, the glycans on infective proteins may additionally attenuate the flexibil-
ity of the host system to lift antibodies against any epitopes that embrace the glycan. 
In an exceedingly T-cell-dependent adaptative immune reaction, peptides from the 
infective agent are presented on antigen- presenting cells by major histocompatibil-
ity complex II molecules, conjointly referred to as human leukocyte antigen (HLA) 
complexes. HLA complexes have the most popular peptide antigen motifs, and sup-
ported data of those preferences it’s doable to predict that peptides in exceedingly 
infective proteins are probably to be HLA antigens [8]. However, once that peptide 
contains a glycosylation site, the probability of the peptide to be presented in an 
HLA complex could also be compromised, if as an example the peptide cannot bind 
to the HLA molecule owing to the steric presence of the glycan. However, glycopep-
tides could also be presented in HLA complexes if the glycan is compact enough or 
if it’s found on the end of the peptide antigen wherever it does not interfere with 
HLA binding. The glycan-mediated shielding of predicted HLA antigens derived 
from the S glycoprotein is conjointly containing a glycosite. Glycosylation system-
atically decreases the surface exposure of the residues proximal to the glycosites 
however conjointly junction rectifier to non-sequential changes in exposure, as a 
result of the 3D topology of the protein surface within the close proximity of every 
glycosite [8, 9].
The SARS-CoV-2 envelope glycoproteins are involved in the viral adhesion and 
entry processes. The presence of glycoproteins in the viral envelope opens up a 
world of possibilities for using carbohydrate-binding agents like lectins to fix some 
of the pandemic’s most pressing issues. Lectins can recognize glycans, allowing 
them to be used in a number of biotechnological applications. The presence of 
glycoproteins on the viral envelope unfolds a large vary of prospects for the applica-
tion of lectins to deal with some urgent issues concerned during this pandemic. The 
growing popularity of glycans enables the use of lectins for many biotechnological 
applications. Significantly, these agglutinins block the viral adhesion to the host 
cells by targeting the sugar moieties in surface proteins, and are considered as 
broad-spectrum inhibitors of viral invasion. The interaction with glycoproteins 
conjointly allows the use of lectins within the development of devices for identifica-
tion and characterization of glycoproteins in a viral envelope or alterations in host 
glycoproteins throughout virus infection. Lectins are natural proteins that focus on 
the sugar moieties of a large vary of glycoproteins [10]. They are prevailing among 
higher plants and are divided into seven families of structurally and evolutionarily 
connected proteins. Over a decade ago, studies revealed that through inhibition of 
virus-cell fusion, plant lectins were reportable to inhibit HIV replication in lympho-
cyte cell cultures [9].
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Sugar-binding proteins that are neither antibodies nor enzymes are known as 
lectins. To be labeled as a lectin, a glycoprotein must meet three distinct criteria. To 
begin, lectin is a carbohydrate-binding protein or glycoprotein (s). Second, lectins 
aren’t the same as immunoglobulins (antibodies). Finally, lectins do not alter the 
biochemistry of the carbohydrates they bind. Plant lectins are a specific type of 
carbohydrate-binding proteins which are capable of specific recognition and revers-
ible binding to carbohydrates. Since lectins can recognize specific carbohydrate 
structures such as proteoglycans, glycoproteins, and glycolipids, they can control 
various cells through glycoconjugates and their physiological and pathological 
phenomena via host-pathogen interactions and cell–cell communications.
Initially, it had been reported that plant lectins inhibit virus replication by 
forestalling virus adsorption however studies had been later shown that they 
prevent the fusion of HIV particles with their target cells. Additionally to the 
antiviral impact of mannose- and N-acetylglucosamine-specific agglutinins on HIV, 
the associate repressive impact of those plant lectins was reported on respiratory 
syncytial viral infection, CMV infection, and influenza A virus infection in vitro. 
Carbohydrate-binding agents are thought of as anti-CoV agents that focus on spike 
protein and restrain CoV entry [10]. They’re proficient to bind specifically with 
the oligosaccharides on virus surfaces like HIV and S glycoprotein. In mouse model 
and additionally, in vitro condition they inhibit a large variety of CoVs, as well as 
SARS-CoV, HCoV NL63, HCoV 229E, and HCoV OC43. Plant lectins, such as those 
present in leeks, have been shown to be effective coronavirus inhibitors by interact-
ing with two targets in the viral replication cycle. The first target was discovered 
early in the replication cycle, most likely during viral attachment, while the second 
was discovered toward the end of the infectious virus cycle. Depending on the 
nature of their sugar specificity, the antiviral activity spectrum of plant lectins var-
ies considerably. In general, the plant lectins which were mannose-specific found 
to be highly effective against coronaviruses. Mannose-binding glycoprotein (MBL; 
additionally called mannan-binding lectin) could be a pattern-recognition molecule 
that plays a critical role in spacing and orientation of the carbohydrate-recognition 
domains [2, 10].
In several expression systems, glycosylation act as a live to gauge antigen quality. 
For styling appropriate immunogens for vaccine development, it is important to 
have basic understanding concomitant with the RBD domain of the SARS-CoV-2 
spike protein which is able to incorporate complicated sialylated N-glycans and 
Figure 1. 
Potential role of MBL in prevention of SARS-CoV2. 1. Attachment of MBL at the glycosylation site of spike 
protein by “Lock and Key” mode. 2. Prevent ACE2 mediated entry of viral pathogen. 3. Lectin pathway-
mediated phagocytosis of intracellular pathogens (adapted from reference [2]).
5
Glycan and Its Role in Combating COVID-19
DOI: http://dx.doi.org/10.5772/intechopen.97240
sialylated glycoprotein O-glycans. The interaction with glycoproteins addition-
ally permits the utilization of lectins within the development of devices for the 
identification and characterization of glycoproteins in infectious agent envelopes or 
alterations in host glycoproteins throughout virus infection. MBL could be a serum 
C-type glycoprotein, that is in a position to bind SARS-CoV intrinsically or infected 
cell and additionally capable to inhibit the infectivity of the virus. Hence, with this 
background knowledge, we could to anticipate that glycosylation of infectious agent 
peptides by “Lock and Key Technology” may be considerate as a novel therapeutic 
strategy against the current COVID-19 pandemic (Figure 1) [2, 10, 11].
2. Glycosylation and its role in onset of disease
The “glycome biology” or “glycobiology” studies the thorough repertoire i.e. the 
structure, biosynthesis, and biology of glycoconjugates composed of carbohydrate 
chains, or glycans, which are covalently, linked to lipid or protein molecules. The 
formation of glycoconjugates, differences in their glycan sequences, their length, 
and the connection between them depends upon on a process called glycosylation. 
Synthesis of glycoconjugate is a dynamic process that relies on the sugar precursors, 
the local milieu of enzymes, structures of organelle as well as cellular signals, and 
the cell types. Studies of rare genetic disorders that have an effect on glycosyl-
ation 1st highlighted the biological importance of the glycome, and technological 
advances have improved our understanding of its heterogeneousness and quality. 
However the replication process of secreted and cell-surface glycomes, overall cellu-
lar standing in health and sickness requires a detail research and assessment. In fact, 
changes in glycosylation will modulate inflammatory responses, alter viral immune 
escape, promote neoplastic cell metastasis, or regulate apoptosis; the composition 
of the glycome conjointly affects urinary organ operate in health and sickness. 
Easy and extremely dynamic protein-bound glycans also are well endowed within 
the nucleus and living substance of cells, wherever they exert restrictive effects. 
In fact, additionally to forming vital structural options, the sugar elements of 
glycoconjugates modulate or mediate a good form of functions in physiological and 
pathophysiological states. Glycoproteins and polysaccharides have vital functions 
in viral cells, and even glycoproteins have central roles within the biology of most 
viruses [10, 12]. Glycoconjugates are measured by the addition of sugars to proteins 
and lipids. A huge range of naturally occurring sugars will be combined to make a 
variety of distinctive glycan structures on lipid and protein molecules that modulate 
their activity. Multiple enzymatic site preferences, similarly because the use of 
stereochemical α or β conjugations, produce diversity in wherever and the way these 
sugars are linked to every alternative. In fact, altogether, these options imply the 
potential existence of ~1012 completely different branched glycan structures.
Protein glycosylation includes the addition of N-linked glycans, O-linked 
glycans, phosphorylated glycans, glycosaminoglycans, and glycosylphosphati-
dylinositol (GPI) anchors to amide backbones similarly to C-mannosylation of 
essential amino acid residues. Glycolipids are glycoconjugate which include glyco-
sphingolipids (GSLs) formed through the addition of sugars to lipids. Glycosylation 
of proteins and lipids happens within the endoplasmic reticulum (ER) and with 
most of the terminal processing occurring within the cis-, medial- and trans-Golgi 
compartments. In these organelles, glycosidases, and glycosyltransferases form 
carbohydrate structures in a series of steps that are dominance by the availability 
of the enzyme activity, substrate, levels of gene transcription, and enzyme loca-
tion. In fact, the glycome of a specific cell reflects its distinctive gene-expression 
pattern that controls the level of the enzymes responsible for glycoconjugation. 
Biotechnology to Combat COVID-19
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The glycome is created in a non-templated manner and is in an elaborate way con-
trolled at multiple levels within the ER and cyst, unlike exome or proteome [12, 13].
3. Different type of glycosylation in human
3.1 N-linked glycosylation
The covalently N-linked glycans are superimposed co-translationally to native 
polypeptides within the endoplasmic reticulum (ER) as blocks of fourteen sugars 
(Glc3Man9GlcNAc2). These glycans are measure then subject to extensive modi-
fication throughout their transport through the ER and also the Golgi body before 
reaching their final destinations within or outside the cell. Within the ER and also the 
early secretory pathway, the sugar repertoire is still very little. Within the Golgi body, 
however, the glycans acquire complicated and extremely numerous structures by ter-
minal glycosylation, which ends up in a very tremendous heterogeneity. Such diversity 
differs between cell sorts, tissues and species, and helps to additional increase micro-
heterogeneity in the presence of the same genetic polypeptide background. This leads 
to the creation of new functionalities and specificities. The N-glycans may also have a 
very important role in correct macromolecule folding and degradation, and solubility, 
by avoiding the precipitation that’s caused by lipophylic aminoacid stretches within the 
emergent polypeptide. The presence of a glycan protect on the peptides additionally 
allows the protection of the glycoproteins against degradation by proteases [13, 14].
3.2 O-linked glycosylation
Glycosylation will occur on amino acids with functional hydroxyl group teams, 
that is most frequently Ser and Thr. In humans, the foremost common sugars joined to 
Ser or Thr are GlcNAc and N-acetylgalactosamine (GalNAc)7. GalNAc-linked glycans 
usually referred to as mucin-type O-glycans, are abundant on various living things 
and secreted glycoproteins together with mucins, which type an important interface 
between animal tissue cells and the external tissue layer surfaces of the body. Mucins 
are characterized by a variable range of tandem repeats with Ser and Thr that create 
many sites for O-glycosylation. O-glycosylation performs various functions, such as 
providing resistance to proteolysis of stem regions of membrane proteins, creating 
specific recognition phenomena, and selection of ligands for selectins. Masking of 
immunogenic epitopes on the protein is in need to special mention [13, 14].
3.3 Glycosphingolipids
GSLs comprise a sphingolipid to which a glycan is connected at the C1 group 
position of a ceramide; they are one in every of the foremost plentiful glycolipids 
in humans are generally found within the lipid bilayers of cellular membranes. GSL 
glycosylation starts with the addition of glucose or galactose to the lipid moiety at 
the protoplasm facet of the ER or the Golgi body; however, the structure is then 
flipped to the luminal side for the additional process. The enzymes that initiate GSL 
glycosylation are specific for lipids, but an additional process of the sugar chain is 
performed by additional general glycosyltransferase [13, 14].
3.4 Proteoglycans and glycosaminoglycans
Proteoglycans are glycoproteins within the extracellular matrix that, in addition 
to containing canonical N-glycans and O-glycans, are characterized by the presence 
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of long sugar repeats connected via O-linked glycosylation motifs [13, 14]. These 
extended sugar chains are termed glycosaminoglycans and contribute to a consider-
able proportion of the proteoglycan’s molecular mass. Whereas N-glycans generally 
embrace 5–12 monosaccharides, a glycosaminoglycan motif will simply contain 
more than eighty sugars (for example, keratan salt is a poly-N-acetyl lactosamine 
chain that contains up to fifty oligosaccharide units). These long chains are con-
structed through oligosaccharide repeats fashioned by GlcNAc or GalNAc, com-
bined with associate uronic acid (that is, glucuronic or iduronic acid) or brain sugar. 
Glycosaminoglycans are functionally various and include heparan salt, chondroitin 
salt, keratin sulfate, and hyaluronan. Glycosaminoglycans are crucial to the forma-
tion of the glycocalyx, an important structure for the upkeep of the cytomembrane 
that conjointly functions as a reservoir for sequestered growth factors [13–15].
3.5 Role of glycans in immunity and inflammation
Cells of the immune system, equally to any or all different cells, express cell 
surface-associated glycoproteins and glycolipids that, besides glycan-binding pro-
teins and different molecules, sense environmental signals. Many immune recep-
tors that are expressed on innate and adaptive immune cells acknowledge glycans 
found on the surface of microorganisms that are referred to as pathogen-associated 
molecular patterns. Examples of such glycan-containing molecules embrace bacte-
rial lipopolysaccharides, peptidoglycans, teichoic acids, capsular polysaccharides, 
and fungal mannans. The recognition of those glycosylated microbial patterns by 
the immune system has been exploited for the vaccine’s development, example dip-
lococcus vaccines, are developed employing a mixture of capsular polysaccharides. 
The recent progress in HIV-1 immunogen development has conjointly been driven 
by a far better understanding of the HIV-1 envelope (Env) conjugated protein and 
the effects of its glycan composition on immune responses and immune evasion 
[15, 16].
Pro-inflammatory cytokines may contribute to inflammatory vascular diseases 
by inducing changes in cell-surface N-glycosylation of epithelial tissue cells. In 
the adaptive immune system, glycans even have crucial and multifarious roles in 
B lymphocyte and lymphocyte differentiation. These functions involve multiple 
cell-surface and secreted proteins (such as CD43, CD45, selectins, galectins, and 
siglecs), differing kinds of cell–cell interactions, and also the recognition of glycan-
containing antigens. The regulation of cellular glycosylation and its impact on the 
molecules that perform as ligands and receptors throughout associate inflammatory 
response is controlled through numerous mechanisms and is dependent on the 
inflammatory insult. These mechanisms, that embrace ERK, and p65 signaling are 
vital to understanding the failure to regulate chronic inflammation in multiple dis-
ease states. Immunoglobulins, for instance, are crucial parts of humoral immunity, 
and altered glycosylation patterns of some antibody isotypes are known in chronic 
inflammatory reaction, and infectious diseases, like arthritis (RA), systemic lupus 
erythematosus (SLE), and HIV infection [16, 17].
The glycoproteins CD43 and CD45 are profusely expressed on the surface of B 
cells and T cells and contain each O-glycans and N-glycans. Glycosylation of those 
proteins is modulated throughout cellular differentiation and activation and regu-
lates multiple T cell functions, as well as cellular migration, T cell receptor signal-
ing, cell survival, and apoptosis. CD45 has an active receptor-like protein tyrosine 
phosphatase domain that interacts with Src family kinases in B cells and T cells to 
control the signaling threshold for the activation of B lymphocyte receptors (BCRs) 
and T cell receptors. CD45 additionally has non-catalytic functions, for instance, in 
modulating the function of the repressive co-receptor CD22 on B cells [17, 18].
Biotechnology to Combat COVID-19
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Siglecs are sialic acid-binding proteins expressed on several cells of the system 
that perform varied functions, as well as the regulation of antigen-specific immune 
responses and cell homing. CD22 is one in all sixteen siglec proteins characterized 
in humans and is expressed on B cells, wherever it specifically binds α-2, 6-linked 
sialic acid-containing ligands; this interaction is crucial for the formation of nano-
clusters within the cell wall that manage BCR signaling following antigen binding 
[17, 18].
The selectin family of proteins consists of E-selectin, P-selectin, and L-selectin 
that are chiefly expressed on epithelium cells, platelets, and leukocytes, respec-
tively. These cell adhesion molecules are vital for white cells rolling on the epithelial 
tissue before tissue extravasations. Another study demonstrates that targeting 
selectins could be helpful in some inflammatory diseases. Immunoglobulin iso-
types disagree within the variety of N-glycans present on their serious chains. 
Some immunoglobulin, such as IgA1 and immune globulin, additionally contain 
O-glycans, which are sometimes clustered within the hinge-region segments 
of these antibodies. Immunoglobulin glycans impact the effect or functions of 
antibodies counting on the branching of N-glycans and/or the terminal sugars of 
N-glycans or O-glycans that embody brain sugar and sialic acid. In fact, immu-
noglobulin glycosylation can verify glycoform is pro-inflammatory, like Ig with 
galactose-deficient N-glycans, or anti-inflammatory drug, like Ig with sialylated 
N-glycans [17–19].
3.6 Glycan and COVID-19
Coronavirus illness 2019 (Covid-19) has a broad clinical spectrum, not never-
theless absolutely delineate or understood, with a regarding the potential for severe 
respiratory illness, multiorgan involvement, and death. As a result of containment 
of the virus has verified to be very troublesome, mitigation efforts like mask-wear-
ing, physical distancing, confinement, and quarantines are enforced worldwide 
leading to restricted exposures/contagious events with also a robust social, health, 
and economic burden [2]. Since ideal preventive ways like repurposing of known 
medication to treat Covid-19, and vaccines associated with inevitably long testing, 
development, and producing time emerges as an attractive approach to timely fulfill 
the continued need.
Glycoproteins of SARS-CoV-2 are concerned with cell adhesion and invasion, 
maturation, and modulation response processes. Though alternative SARS-CoV-2 
proteins have foreseeable glycosylation sites (such as M-protein, E-protein), the 
bulk of experimental knowledge is presently accessible on the S-protein. This might 
be a trimeric protein that mediates viral adhesion through binding to the human 
angiotensin-converting accelerator two (hACE2) and conjointly interacts with the 
host immune defense [19, 20].
The S-protein from SARS-CoV-2 has 2 practical subunits (S1 and S2) with 23 
potential sites for N-glycosylation and O-glycosylation. Some variations within the 
glycosylation sites repertoire and famed epitopes are rumored for the SARS-CoV-2 
spike protein, despite it’s similarity with the SARS-CoV spike (approximately 
87.2%). The oligo mannose-type glycans were predominant in 2 sites (N234 and 
N709). Complex-type glycans were preponderantly exhibited in fourteen organic 
compound residues (N17, N74, N149, N165, N282, N331, N343, N616, N657, N1098, 
N1134, N1158, N1173, and N1194), whereas six sites showed a combination of 
oligomannose- and complex-type glycans (N1074, N801, N717, N603, N122, and 
N61). The foremost common configuration of oligomannose-type glycans was 
Man5GlcNAc2. Afucosylated and fucosylated hybrid-type glycans were detected 
in a minimum of 9 sites. Studies highlighted that the glycosylation profile of the 
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SARS-CoV-2 S-protein was completely different from those discovered for host 
glycoproteins or for alternative engulfed viruses. Another experimental study 
revealed the configuration of the N-glycosylation and O-glycosylation of spike 
protein subunits, even in the HEK293-based expression system. The authors have 
solved the structures of N-linked glycans in seventeen foretold sites and rumored 
the presence of three categories of N-glycans. Significantly, this study discovered 
O-glycosylation modifications on 2 residues (Thr323 and Ser325) present within 
the receptor-binding domain (RBD) of the S1 monetary unit. Recently, the charac-
terization of the glycosylation profile of the S-protein expressed in BTI-Tn-5B1–4 
insect cells was rumored to show the presence of high-mannose N-glycans alto-
gether twenty two foretold sites. Apparently, these glycans cowl most of the RBD 
space [17, 20].
The glycan shield plays a vital role in hiding the S protein surface from molecular 
recognition. However, to effectively operate, the spike has to recognize and bind to 
ACE2 receptors as the primary host cell infection route. For this reason, the RBM 
should become totally exposed and accessible. During this state of affairs, the 
glycan shield works in concert with an oversized conformational amendment that 
permits the RBD to emerge on top of the N-glycan coverage. The glycans protect the 
RBD region that does not directly act with ACE2 by “up” and “down” conforma-
tions. Ultimately, this analysis shows that the RBM is often accessible once RBD 
is “up”, whereas it’s terribly well camouflaged when “down”. This implies that the 
glycan shield of this vital domain is effectively paired with its “down-to-up” con-
formational amendment, allowing the RBM to transiently emerge from the glycan 
shield and bind to ACE2 receptors [16, 19, 20].
Protein glycosylation plays a crucial role in the infective agent pathological pro-
cess, as incontestable by the characteristically thick N-glycan coating of the infec-
tive agent fusion proteins. Within the HIV-1 envelope spike (Env), as an example, 
the protein-accessible expanse is nearly entirely coated in N-glycans. These are thus 
densely packed that they account for quite half the protein’s mass. The N-glycans 
present on the surface of viral envelope glycoproteins show terribly diverse type 
of biological roles. Infective agent entry through membrane fusion is initiated by 
envelope glycoproteins through molecular recognition events involving cell surface 
receptors, which are usually mediated by specific N-glycan epitopes. Furthermore, 
an extremely dense coating of nonimmunogenic or frail immunogenic advanced 
carbohydrates on otherwise perilously exposed infective agent proteins constitutes 
a perfect camouflage (or shield) to evade the immune system. To the current study, 
the HIV-1 Env glycan defends, which is essentially structured by oligomannose 
(Man5–9) N-glycans, has been shown to be quite effective in allowing the virus to 
thwart the system [16, 17, 19].
4. Therapeutic approach of glycomedicine
Developments within the field of glycobiology have enabled the development 
of a range of glycan-based medical specialties. As an example, envelope conjugated 
protein gp120 is expressed on the surface of HIV-1, and its variable glycosylation 
facilitates viral escape from immune detection. Adding new glycan-dependent 
epitopes to the recombinant gp120 used for vaccination inflated the ability of 
broadly speaking neutralizing being antibodies to recognize HIV-1, suggesting that 
this approach is used to optimize vaccination protocols and antigens. Moreover, 
HIV-1 envelope glycoproteins not solely differentiate HIV-1 clad however can even 
be wont to estimate the efficacy of vaccine regimens on the premise of protein bind-
ing to a panel of gp120 glycan-dependent epitopes 240. As printed antecedently, 
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glycosylation plays an important role in regulating purposeful immune responses 
through complex receptor–glycan motif interactions. This site is currently being 
exploited in Ig therapies [20].
4.1 Role of lectins in COVID 19 and activation of complement pathway
Lectins, are glycan-binding proteins (GBPs) that are present in plants and lots of 
alternative species, are known to act with various glycan molecules either attached 
or released to a peptide backbone. This distinctive property has been explored 
within the development of analytics for glycan determination. Many relevant 
platforms are according to which lectin-based microarray has incontestable a utility 
in capturing glycan profiles of therapeutic compound glycoprotein [21].
As antecedently mentioned, the S-protein of SARS-CoV-2 encompasses a crucial 
role in infectious agent adhesion by binding to hACE2. Therefore, the disruption 
of this interaction is taken into account as a gorgeous target for antiviral medi-
cal care. Some non-mammalian-derived lectins (from plants and bacteria) are 
pointed as various antiviral agents against swallowed viruses thanks to their ability 
to acknowledge the glycans present within the structural proteins and to impair 
the initial steps of the infectious agent pathological process. Given the recent 
emergence of SARS-CoV-2, solely the glycoprotein isolated from Indian bean [Flt3 
receptor-interacting glycoprotein (FRIL)] has been according up to now as an 
antiviral against this virus. FRIL may be a glucose/mannose glycoprotein conjointly 
called DLL-I. This protein molecule utterly inhibited the cytopathic result of 
SARS-CoV-2 (strain hCoV-19/Taiwan/NTU04/2020) toward Vero cells at higher 
concentrations [17, 21].
According to a study, evaluation of the in vitro antiviral activity of thirty three 
plant lectins toward coronaviruses (SARS-CoV and feline infectious redness virus). 
Mannose-binding agglutinins showed the best anti-SARS-CoV effects. Among 
the studied lectins, the upper selective indexes (SIs) were found for those isolated 
from alliaceous plant (APA; SI > 222.2), black mulberry (Morniga M II; SI > 62.5), 
and helleborine (EHA; SI > 55.5). Nettle (UDA) and common tobacco agglutinins 
(NICTABA), each specific for GlcNAc, conjointly showed promising activity. 
NICTABA and FTO have conjointly shown restrictive activity against different 
swallowed viruses as well as respiratory disease A/B, breakbone fever virus kind a 
pair of (DENV-2), herpes simplex virus varieties one and a pair of (HSV-1 and HSV-
2) and human immunological disorder viruses (HIV-1/2). Other plant lectins are 
shown to exhibit restrictive action toward different coronaviruses. Some mannose-
binding lectins: concanavalin A (Con A), amaryllis hybrid antibody (HHA), 
Galanthus nivalis antibody (GNA or GNL) one in every of these studies highlighted 
the importance of glycosylation within the sensibility of 2 kinds of coronaviruses 
(mouse liver disease virus and feline infectious redness virus) (Figure 2) [17, 21].
Non-plant-derived agglutinins also are pointed as promising agents 
against coronaviruses, e.g. the mannose-binding-lectins cyanovirin-N (from 
Cyanobacterium protoctiste) ellipsosporum and griffithsin (GRFT) (from red 
marine alga Griffithsia sp.) However, solely GRFT has been evaluated against 
SARS-CoV and MERS-CoV. This protein molecule binds to multiple sites of 
SARS-CoV and MERS-Cov glycoproteins with high affinity and inhibits infec-
tious agent entry. In addition, this glycoprotein conjointly reduced the mortality 
and therefore the severity of fatal pneumonic infection iatrogenic by SARS-CoV 
in mice. This result is related to the decrease of pro-inflammatory cytokines in 
infected respiratory organ tissue [17–19, 21].
The mitogenicity and pro-inflammatory properties of lectins raise many que-
ries relating to their worth to treat clinical conditions with severe inflammatory 
11
Glycan and Its Role in Combating COVID-19
DOI: http://dx.doi.org/10.5772/intechopen.97240
elements, as seen in COVID-19. The broad-spectrum activity of those agents and 
therefore the techniques utilized in their style ought to be thought of within the 
hunt for anti-infective compounds toward SARS-CoV-2. These compounds ought 
to enhance the response iatrogenic by the immunogen, whereas keeping the equi-
librium between body substance and cellular immune responses. Noteworthy to say 
that even the right induction of Th1-biased response, which is very important for 
defense against infectious agents, still remains a limitation for a few adjuvants.
Lectins are well-known to push the proliferation of lymphocytes and modulate 
the discharge of effectors molecules (cytokines and gas oxide) by immune cells. 
For example, many lectins are potent inducers of IL-12 and IFN-γ production 
that are key cytokines in the establishment of the Th1 axis. Some lectins may 
also bind to toll-like receptors and/or increase their expression levels, which can 
conjointly modulate the discharge of pro-inflammatory cytokines and increase 
the receptor’s ability to acknowledge the pathogens. In fact, the improvement of 
Th1-based response is very important for protecting immunity against viruses and 
different intracellular pathogens thanks to the activation of cytotoxic cells (natural 
killer cells and TCD8 lymphocytes) and production of neutralizing antibodies 
concerned in immunologic memory. During this sense, the immunomodulatory 
properties of lectins build them attractive candidates for vaccine adjuvant. Some 
studies involving glycoprotein as an adjuvant for respiratory disease vaccines need 
special mention [21].
Innate immunity plays an essential role against numerous pathogens, in that, 
physical barriers complement components, coagulation cascade, antigen-presenting 
cells, and immunoglobulins synergistically regulate opsonisation, inflammation, 
and phagocytosis. Although the innate system might not determine each antigen 
getting into the host, it will acknowledge numerous microorganisms mainly based 
on pathogen-associated molecular patterns (PAMPs) present on the cell surface. 
The notable examples of PAMPs are bacterial peptidoglycan, lipopolysaccharides, 
mannans, lipoteichoic acids, bacterial DNA, double-stranded ribonucleic acid, 
glucans, and infective agent surface macromolecule. Duly, the complement system 
could be a wing of an innate immune response having varied biological effects 
against a good vary of bacteria, fungal, and infective agent infections [22].
The complement cascade consists of soluble factors and cell surface recep-
tors which will sensitize and counteract against both invading and self-antigens. 
The complement system bridges the innate and accommodative reaction through 
Figure 2. 
Crystal structure of different mannose specific lectins (structures adapted from RCSB PDB).
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humoral immunity, and by modulating T- and B-cell functions. Complement 
pathways, which, once activated, lead to consecutive protein reactions, breakdown 
of complement components C3 and C5, and end in by-products formation (C3a and 
C5a). These anaphylatoxins elicit an excessiveness of physiochemical responses that 
successively activate phagocytic cells, and release cytokines, chemokines, reac-
tive element species (ROS), adhesion molecules, and inflammation at the site of 
infection. Immunoglobulin and cytokines are essential parts of antiviral immunity. 
In fact, there are 3 main phases of complement activation - (1) foreign molecule 
recognition, (2) convertase enzyme formation which will cleave C3 and C5, and (3) 
fabrication of MAC for cell lysis. The alternative, classical, and mannose-binding 
lectin (MBL) pathways are activation cascades of assorted host-pathogen interac-
tion conditions, joining at the juncture C3, from wherever the central complement 
cascade proceeds. Among the 3 pathways of complement activation, the MBL 
pathway is primary in infective agent infections to induce a pro-inflammatory 
response. Detail Investigations involving the complement system activation by the 
lectin pathway in COVID-19 and diseases are in need of the hour [22, 23].
5. Conclusion
Glycosylation could be a common modification of proteins and lipids that 
involves non-template dynamic and complex processes. Glycans have multiple cru-
cial roles in cellular responses to environmental stimuli likewise as cellular growth 
and differentiation; specific changes in glycan composition are directly joined 
to several diseases. Technological advances are commencing to overcome many 
of the challenges display by the complexities of glycoconjugates, improving our 
understanding of the physiological and pathological processes that are regulated by 
glycans.
The application of lectins to unravel differing types of issues involved in viral 
infections like COVID-19 depends upon the presence of glycoproteins within the 
viral envelope. Within the therapeutic space, the lectins can be thought-about lead-
ing molecules for the event of the latest antiviral approaches because of their ability 
to inhibit microorganism entry within the host cell. The advances in glycoprotein 
style methods are necessary to spice up the clinical application of those agents 
thought-about for the treatment of SARS-CoV-2 and alternative microorganism 
infections. The immunomodulatory action of some lectins may also be exploited to 
boost the effectiveness of immunization schemes for microorganism infections.
On the opposite hand, lectin–carbohydrates interactions will be accustomed 
style devices for diagnosing targeting microorganism glycoproteins or host glyco-
proteins alterations throughout microorganism infections. This kind of apparatuses 
hold the promise of producing sensitive, quick, and cost-effective identification of 
infected people and are of important would like throughout the pandemic things, as 
obligatory for COVID-19.
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